12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Insulin degludec: Phase III data

The open-label, international Phase III NN1250-3770 trial in about 493 Type I diabetics showed that a flexible dosing regimen of once-daily subcutaneous insulin degludec met the primary endpoint of non-inferiority to Lantus insulin glargine in reducing HbA1c...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >